Olav Bjorn Petersen

Olav Bjorn Petersen

Auto-generated profile, based on publicly available information

Olav Bjorn Petersen

Center for Fetal Medicine, Pregnancy and Ultrasound, Department of Gynecology, Fertility and Obstetrics Copenhagen University Hospital Rigshospitalet, Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
APA. G. Pedersen
A. G. Pedersen
OPO. B. Petersen
O. B. Petersen
PWP. Wara
P. Wara
HRH. Rønning
H. Rønning
NQNiels Qvist
Niels Qvist
SLS. Laurberg
S. Laurberg

1 September 2018 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
RLRebekka Lytzen
Rebekka Lytzen
NVNiels Vejlstrup
Niels Vejlstrup
JBJesper Bjerre
Jesper Bjerre
OPOlav Bjørn Petersen
Olav Bjørn Petersen
SLStine Leenskjold
Stine Leenskjold
LSLars Søndergaard
Lars Søndergaard
The reported incidence of congenital heart disease (CHD) varies from 0.8% to 1.5%.1-3 However, there are a limited number of nationwide population-based studies examining the incidence of CHD and even fewer that include termination of pregnancies (TOP). Termination of pregnancy rates vary according to cultural and religious differences, as well as prenatal detection rates for CHD. Different approaches to prenatal screening exist worldwide, ranging from on indication only to the routine practice of 3 ultrasonographic scans during pregnancy.4-6 Furthermore, access to routine scans may vary within a country owing to geographical, social, and economic limitations.

19 November 2015 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
CWC. B. Wulff
C. B. Wulff
TGT. A. Gerds
T. A. Gerds
LRLine Rode
Line Rode
CEC. K. Ekelund
C. K. Ekelund
OPO. B. Petersen
O. B. Petersen
TGthe Danish Fetal Medicine Study Group
the Danish Fetal Medicine Study Group
Objective: To assess prospectively the risk of fetal loss associated with chorionic villus sampling (CVS) and amniocentesis (AC) following combined first‐trimester screening (cFTS) for Down syndrome.Methods: This was a nationwide population‐based study (Danish Fetal Medicine Database, 2008–2010) including 147 987 women with singleton pregnancy who underwent cFTS. Propensity score stratification was used to assess the risk of fetal loss with and without invasive testing. Analyses were performed between 3 and 21 days after cFTS for CVS and between 28 and 42 days after cFTS for AC. Results are reported as average risk differences with 95% CIs.Results: The risks of miscarriage and stillbirth were not higher in women exposed to CVS or AC compared with unexposed women, independent of the analysis time‐point. The average effect of CVS on risk of miscarriage was –0.08% (95% CI, −0.64; 0.47) at 3 days and –0.21% (95% CI, –0.58; 0.15) at 21 days after cFTS, while the effect on risk of stillbirth was –0.18% (95% CI, –0.50; 0.13) at 3 days and –0.27% (95% CI, –0.58; 0.04) at 21 days after cFTS. Regarding the effect of AC on risk of miscarriage, the analysis at 28 days after cFTS showed an average effect of 0.56% (95% CI, –0.21; 1.33), while the effect on risk of stillbirth was 0.09% (95% CI, –0.39; 0.58) at 42 days after cFTS.Conclusion: Neither CVS nor AC was associated with increased risk of miscarriage or stillbirth. These findings indicate that the procedure‐related risk of CVS and AC is very low. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.

6 December 2013 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
OPO. B. Petersen
O. B. Petersen
IVIda Vogel
Ida Vogel
CEC. Ekelund
C. Ekelund
JHJ. Hyett
J. Hyett
ATA. Tabor
A. Tabor
TGthe Danish Clinical Genetics Study Group
the Danish Clinical Genetics Study Group
Objectives: Targeted non‐invasive prenatal testing (NIPT) tests for trisomies 21, 18 and 13 and sex chromosome aneuploidies and could be an alternative to traditional karyotyping. The aim of this study was to determine the risk of missing other abnormal karyotypes of probable phenotypic significance by NIPT.Methods: This was a retrospective population‐based analysis of all singleton pregnancies booked for combined first‐trimester screening (cFTS) in Denmark over a 4‐year period. Data concerning maternal demographics, cFTS and prenatal or postnatal karyotypes were collected from the Danish Fetal Medicine database. Karyotypes were classified according to whether the chromosomal anomaly would have been detected by NIPT and whether it was likely to affect phenotype.Results: cFTS was completed in 193 638 pregnancies. 10 205 (5.3%) had cytogenetic or molecular analysis performed. Of these, 1122 (11.0%) had an abnormal karyotype, of which 262 (23.4%) would have been missed by NIPT, but would probably have been clinically significant. The prevalence of such ‘atypical abnormal karyotypes’ was increased in women above 45 years of age, in pregnancies with increased nuchal translucency (NT) thickness (≥ 3.5 mm), with abnormal levels of free β‐human chorionic gonadotropin (< 0.2 or ≥ 5.0 multiples of the median (MoM)) or pregnancy‐associated plasma protein‐A < 0.2 MoM. One or more of these factors was present in 3% of women, and the prevalence of atypical abnormal karyotypes in this high‐risk cohort was 1.6%.Conclusions: A significant proportion of karyotypic abnormalities will be missed by targeted NIPT. Women of advanced maternal age, or with increased fetal NT or abnormal biochemistry, have a higher risk of having a fetus affected by an atypical abnormal karyotype and need to be counseled accordingly when considering NIPT. Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd

23 July 2010 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
DWD. Wright
D. Wright
KSK. Spencer
K. Spencer
KKK. Kagan K
K. Kagan K
NTN. Tørring
N. Tørring
OPO. B. Petersen
O. B. Petersen
KNKypros Herodotos Nicolaides
Kypros Herodotos Nicolaides
Objective: To establish an algorithm for first‐trimester combined screening for trisomy 21 with biochemical testing from 7 to 14 weeks' gestation and ultrasound testing at 11–13 weeks.Methods: This was a multicenter study of 886 pregnancies with trisomy 21 and 222 475 unaffected pregnancies with measurements of free β‐human chorionic gonadotropin (β‐hCG) and pregnancy‐associated plasma protein‐A (PAPP‐A) at 7–14 weeks' gestation. Multiple regression modeling of log‐transformed marker values was used to produce log multiples of the median (MoM) values for PAPP‐A and free β‐hCG. The models included terms for the center attended and the machine used for biochemical analysis, gestational age, maternal racial origin, maternal weight, smoking status and method of conception. Bivariate Gaussian distributions were fitted to log MoM PAPP‐A and log MoM free β‐hCG in trisomy 21 and in unaffected pregnancies. In each case the patient‐specific risk for trisomy 21 was estimated by multiplying the individual maternal age‐related risk with the likelihood ratio (LR) for fetal nuchal translucency (NT) according to the mixture model and the combined LR for maternal serum free β‐hCG and PAPP‐A. Estimates of detection rates for trisomy 21 and false‐positive rates were calculated for combined screening with measurements of NT at 12 weeks together with measurements of free β‐hCG and PAPP‐A from 8 to 13 weeks.Results: In trisomy 21 pregnancies the mean log MoM free β‐hCG increased linearly with gestation between 7 and 14 weeks, whereas the relation between log MoM PAPP‐A and gestation was fitted by a quadratic equation such that the maximum separation between trisomy 21 and unaffected pregnancies occurs at 9–10 weeks. At a false‐positive rate of 3% the detection rate of combined screening at 12 weeks was 86% and this increased to 90% by biochemical testing at 9 weeks and ultrasound scanning at 12 weeks. The detection rate increased to 92% by measuring PAPP‐A at 9 weeks and free β‐hCG at the time of the scan at 12 weeks.Conclusion: The performance of first‐trimester biochemical screening for trisomy 21 is best at 9–10 weeks rather than at 7–8 or 11–14 weeks. Copyright © 2010 ISUOG. Published by John Wiley & Sons, Ltd.

27 September 2010 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
HMH. N. Madsen
H. N. Madsen
SBS. Ball
S. Ball
DWD. Wright
D. Wright
NTN. Tørring
N. Tørring
OPO. B. Petersen
O. B. Petersen
KSK. Spencer
K. Spencer
Objective: To estimate the difference between levels of the two biochemical markers pregnancy‐associated plasma protein‐A (PAPP‐A) and maternal serum free β‐human chorionic gonadotropin (free β‐hCG) in twin pregnancies relative to singleton pregnancies and establish an improved screening procedure for chromosomal abnormalities such as trisomy 21 in twin pregnancies.Methods: 4843 unaffected and 47 trisomy 21‐affected twin pregnancies were included in the study. Chorionicity‐specific medians were generated for PAPP‐A and free β‐hCG from gestational ages 8 to 14 weeks. Multiple of the median values for each of the biochemical markers were calculated. Detection rates and false‐positive rates were estimated for screening tests incorporating nuchal translucency and maternal age, with and without biochemistry.Results: Medians for the two biochemical markers for monochorionic and dichorionic twins in unaffected pregnancies show a gestational age‐specific increase relative to singleton medians. Allowing for gestation and chorionicity, twin pregnancies affected with trisomy 21 had higher levels of free β‐hCG and lower levels of PAPP‐A. Adding biochemistry into the risk assessment using a fixed risk cut‐off of 1 in 100 increased the detection rate for fetal trisomy 21 in dizygotic twin pregnancies from 78 to 90%, and decreased the false‐positive rate from 8.0 to 5.9%.Conclusion: Generation of chorionicity‐specific medians for the biochemical markers and their use in risk assessment can improve the performance of first‐trimester screening for chromosomal abnormalities in twins to a level comparable with that in singleton pregnancies. Copyright © 2010 ISUOG. Published by John Wiley & Sons, Ltd.